1. Home
  2. TBPH vs EVLV Comparison

TBPH vs EVLV Comparison

Compare TBPH & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.73

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Logo Evolv Technologies Holdings Inc.

EVLV

Evolv Technologies Holdings Inc.

HOLD

Current Price

$6.72

Market Cap

988.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
EVLV
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
993.7M
988.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TBPH
EVLV
Price
$18.73
$6.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$27.80
$9.13
AVG Volume (30 Days)
601.0K
3.2M
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.58
N/A
Revenue
$80,327,000.00
$136,501,000.00
Revenue This Year
$70.78
$31.08
Revenue Next Year
N/A
$17.33
P/E Ratio
$32.19
N/A
Revenue Growth
27.12
43.16
52 Week Low
$7.90
$2.64
52 Week High
$20.33
$8.91

Technical Indicators

Market Signals
Indicator
TBPH
EVLV
Relative Strength Index (RSI) 58.73 50.77
Support Level $18.39 $6.10
Resistance Level $20.32 $6.35
Average True Range (ATR) 0.87 0.33
MACD -0.05 0.11
Stochastic Oscillator 53.71 89.34

Price Performance

Historical Comparison
TBPH
EVLV

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: